Zenas BioPharma, Inc. competitors & alternatives

Immunitas Therapeutics, Inc.BiotechnologyUnited States

71% matchPrivate

Biotechnology

Immunitas Therapeutics, Inc. is a US-based biotechnology company established in 2019 and headquartered in Waltham, Massachusetts. The company focuses on pioneering novel therapeutic treatments in immunology and oncology.

Biotechnology

Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.

Similar biotech company

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Similar biotech company

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.

Zag BioBiotechnologyUnited States

69% match

Biotechnology

Zag Bio is a biotechnology research company headquartered in Cambridge, Massachusetts. The enterprise focuses on developing innovative therapies for autoimmune diseases by targeting the thymus gland to engage the body's natural T cell central tolerance mechanisms.

VACCINEX, INC.VCNX · BiotechRochester, United States

69% matchPublic

Similar biotech company

Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.

Biotechnology

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.

Biotechnology

Q32 Bio Inc. is a clinical-stage biotechnology company, headquartered in Waltham, Massachusetts, focused on creating innovative biologic treatments. Operating within the United States, its primary objective is to re-establish a healthy immune balance in individuals suffering from autoimmune and inflammatory conditions stemming from pathological immune dysfunction. The company's primary therapeutic candidate, ADX-097, is a humanized monoclonal antibody fusion protein engineered to restore proper complement regulation. This compound has successfully concluded its Phase I clinical trial and is being advanced for the treatment of severe renal and other complement-mediated diseases that present significant unmet medical needs. These include specific conditions like lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. Furthermore, Q32 Bio is progressing Bempikibart (ADX-914), a fully human monoclonal antibody that functions as an interleukin-7 receptor alpha antagonist. By disrupting the signaling pathways mediated by interleukin-7 and thymic stromal lymphopoietin, Bempikibart aims to normalize adaptive immune function. This promising candidate is currently undergoing Phase II clinical trials for the management of atopic dermatitis and alopecia areata. The company, established in 2017, was previously known as AdMIRx Inc. and rebranded to Q32 Bio Inc. in April 2020.

Ocean Biomedical, Inc.OCEA · BiotechProvidence, United States

68% matchPublic

Similar biotech company

Ocean Biomedical, Inc. operates as a biopharmaceutical firm committed to identifying and advancing novel therapeutic solutions for various medical challenges, including cancer, fibrotic disorders, infectious illnesses, and inflammation. The company's pipeline includes the development of both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are specifically designed to target Chi3l1, offering potential treatments for non-small cell lung cancer and glioblastoma multiforme. Additionally, they are progressing a small molecule drug candidate aimed at Chit1, intended to address Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Leveraging its proprietary WPDS platform, Ocean Biomedical is also developing three further product candidates. These encompass a promising malaria vaccine, a humanized mAb therapeutic for malaria that targets the Plasmodium falciparum glutamic-acid-rich protein (PfGARP), and a small molecule malaria therapeutic also designed to interact with PfGARP. Furthermore, a treatment candidate for hospitalized COVID-19 patients is also under development. The company, established in 2019, maintains its operations in Providence, Rhode Island.

Biotechnology

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.

Oblenio BioBiotechnologyUnited States

68% match

Biotechnology

Oblenio Bio is a biotechnology research company headquartered in Lexington, Massachusetts, focused on transforming the treatment of refractory autoimmune diseases by delivering a broad immune system reset.

Xenetic Biosciences, Inc.XBIO · BiotechFramingham, United States

68% matchPublic

Similar biotech company

Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.